BioNexus Gene Lab (BGLC) Net Margin (2018 - 2026)

BioNexus Gene Lab (BGLC) has 9 years of Net Margin data on file, last reported at 2379.72% in Q1 2026.

• For the quarter ending Q1 2026, Net Margin fell 235055.0% year-over-year to 2379.72%; the trailing twelve-month figure through Mar 2026 stood at 54.7% (down 3184.0% YoY), and the FY2025 full-year result was 40.2%, down 2339.0% from the prior year.
• Net Margin slipped to 2379.72% in Q1 2026, from 214.18% in the prior quarter.
• In the past five years, Net Margin ranged from a high of 15.46% in Q4 2023 to a low of 2379.72% in Q1 2026.
• A 5-year average of 167.3% and a median of 11.35% in 2023 frame the typical range for Net Margin.
• Across the five-year window, Net Margin soared 5103 bps in 2024 and tumbled 235055 bps in 2026, its largest moves.
• Tracing BGLC's Net Margin over 5 years: stood at 2.32% in 2022, then soared by 567 bps to 15.46% in 2023, then plunged by 189 bps to 13.8% in 2024, then plunged by 1452 bps to 214.18% in 2025, then slumped by 1011 bps to 2379.72% in 2026.
• Business Quant data shows BGLC's Net Margin at 2379.72% in Q1 2026, 214.18% in Q4 2025, and 27.87% in Q3 2025.